Myopericarditis following both BNT162b2 and NVX-CoV2373

Saima Ahmad; Chino Yuson; Adrianna Le; Pravin Hissaria

doi:10.1186/s13223-022-00750-7

Myopericarditis following both BNT162b2 and NVX-CoV2373

Allergy Asthma Clin Immunol. 2022 Dec 23;18(1):109. doi: 10.1186/s13223-022-00750-7.

Authors

Saima Ahmad^{1

2}, Chino Yuson^{3

4}, Adrianna Le³, Pravin Hissaria^{3

4

5}

Affiliations

¹ Royal Adelaide Hospital, Port Road Adelaide, Adelaide, SA, 5000, Australia. saima.ahmad@sa.gov.au.
² , Adelaide, SA, 5000, Australia. saima.ahmad@sa.gov.au.
³ Royal Adelaide Hospital, Port Road Adelaide, Adelaide, SA, 5000, Australia.
⁴ The University of Adelaide, Adelaide, Australia.
⁵ SA Pathology, Adelaide, Australia.

Abstract

Background: Myopericarditis is a well reported complication associated with SARS-Cov-2 (COVID-19) infection and vaccinations; particularly with mRNA vaccines (BNT162b2 and mRNA-1273), and in the young male population. The risk-to-benefit ratio in sequential vaccination dosing in young males is further clouded in the era of the omicron variant with its reported enhanced immune escape.

Study design: A case series of two cases of post vaccination myopericarditis following the NVX-CoV2373 after also developing myopericarditis with BNT162b2.

Conclusion: To our knowledge, we are the first to describe post vaccination myopericarditis following NVX-CoV2373 after also developing myopericarditis with BNT162b2. The similarities in presentation between the reactions of both platforms would suggest a similar pathogenesis, although the exact mechanism remains unknown. Further studies are necessary to identify these mechanisms, as well as to identify biomarkers that may identify vulnerable populations. On-going vigilance is necessary to identify those who may be at an increased risk of post-COVID vaccine myopericarditis.

Keywords: BNT162b2; COVID-19; Myocarditis; Myopericarditis; NVX-CoV2373; Pericarditis; SARS-Cov-2; Vaccination; mRNA-1273.